Comprehensive Reference for Certified Research Personnel
Version 1.0 - 2026
Peptides are short chains of amino acids (2-50 amino acids) that serve as signaling molecules within biological systems. Unlike larger proteins, peptides are easily absorbed and can target specific pathways without causing widespread disruption to natural processes.
Research Context
This guide is intended exclusively for certified research personnel conducting authorized peptide studies. All protocols must be performed in compliance with institutional guidelines and regulatory requirements.
NNMT Inhibitor for Metabolic Enhancement
Mechanism: Inhibits NNMT enzyme, boosting NAD+ production and mitochondrial function
Research Dosage: 50-100 mg/day (oral capsules), 4-8 week protocols
Key Findings: Improves metabolic efficiency and fat-burning at cellular level, even at rest
Targeted Fat Loss Peptide
Mechanism: GH fragment (176-191) promoting fat breakdown without affecting blood sugar
Research Dosage: 250-500 mcg once daily, 8-12 week protocols
Key Findings: 12-week trial showed 2.8 kg average weight loss with selective fat reduction
Synergistic Growth Hormone Stack
Mechanism: GHRH analog + ghrelin receptor agonist for sustained GH release
Research Dosage: 200-300 mcg each, 1-2x daily, 8-12 week protocols
Key Findings: 200-1000% increase in GH levels, enhanced lipolysis and muscle preservation
Visceral Fat Reduction Specialist
Mechanism: GHRH analog targeting visceral adipose tissue
Research Dosage: 2 mg/day (5 days/week), 8-12 week protocols
Key Findings: FDA-approved data shows 9.9% reduction in visceral fat over 6 months
Body Protection Compound
Mechanism: Pentadecapeptide promoting angiogenesis and tissue regeneration
Research Dosage: 250-500 mcg, 1-2x daily, 4-6 week protocols
Key Findings: Accelerates healing of tendons, ligaments, muscles, and gut lining
Thymosin Beta-4 for Tissue Repair
Mechanism: Promotes cell migration and reduces inflammation
Research Dosage: 2-2.5 mg, 2x/week loading, then 1x/week maintenance
Key Findings: Cardioprotective effects and improved tissue quality during healing
Triple Agonist for Maximum Fat Loss
Mechanism: GLP-1, GIP, and glucagon receptor agonist
Research Dosage: 0.5-1.0 mg/week starting, titrate to 8-12 mg/week, 12-48 weeks
Key Findings: Clinical trials show up to 24.2% body weight loss over 48 weeks
Dual Incretin for Weight Management
Mechanism: Dual GLP-1 and GIP receptor agonist
Research Dosage: 2.5 mg/week starting, increase to 15 mg/week, 12-88 weeks
Key Findings: SURMOUNT trials show 25.3% weight loss over 88 weeks
GLP-1 Agonist for Metabolic Control
Mechanism: GLP-1 receptor agonist for appetite and glucose regulation
Research Dosage: 0.25 mg/week starting, titrate to 2.4 mg/week, 12-104 weeks
Key Findings: STEP trials demonstrate 15.2% weight loss over 104 weeks
⚠️ Sterile Technique Required
All reconstitution procedures must be performed using aseptic technique in appropriate laboratory conditions by trained personnel.
Step 1: Preparation
Allow peptide vial to reach room temperature (15-20 minutes). Gather bacteriostatic water, sterile syringes, and alcohol swabs.
Step 2: Sanitization
Clean rubber stoppers of both peptide vial and bacteriostatic water with alcohol swabs. Allow to air dry completely.
Step 3: Draw Bacteriostatic Water
Using sterile syringe, draw calculated amount of bacteriostatic water. Remove air bubbles by tapping syringe gently.
Step 4: Inject Solution
Insert needle at 45° angle. Inject water slowly down the side of vial, never directly onto powder. This prevents peptide degradation.
Step 5: Gentle Mixing
Swirl vial gently in circular motion. Never shake. Allow 2-3 minutes for complete dissolution. Solution should be clear.
Basic Formula
Dose (mcg) ÷ Total mcg in vial × Total mL = mL to draw
BPC-157 (5mg vial + 2mL bacteriostatic water)
Target dose: 250 mcg
250 mcg ÷ 5000 mcg × 2 mL = 0.1 mL (10 units on insulin syringe)
CJC-1295 + Ipamorelin (5mg each + 2mL per vial)
Target dose: 200 mcg each
200 mcg ÷ 5000 mcg × 2 mL = 0.08 mL (8 units) from each vial
TB-500 (5mg vial + 2mL bacteriostatic water)
Target dose: 2 mg (2000 mcg)
2000 mcg ÷ 5000 mcg × 2 mL = 0.8 mL (80 units)
Semaglutide (5mg vial + 2mL bacteriostatic water)
Target dose: 0.25 mg (250 mcg) - Week 1
250 mcg ÷ 5000 mcg × 2 mL = 0.1 mL (10 units)
Essential Supplies
Storage Equipment
Quality Standards
⚠️ Critical Safety Requirements
| Parameter | Relevance | Frequency |
|---|---|---|
| IGF-1 Levels | Monitor GH peptide exposure | Every 4-6 weeks |
| Fasting Glucose & HbA1c | Insulin sensitivity tracking | Baseline, then monthly |
| Lipid Panel | Cardiovascular markers | Every 8-12 weeks |
| Liver Enzymes | Hepatic function | Baseline, then as needed |
| Thyroid Panel | T3/T4 with GH peptides | Every 12 weeks |
Do Not Use In:
Lyophilized (Powder) Form
Reconstituted Form
Temperature Monitoring
Maintain detailed temperature logs for all storage units. Any temperature excursion outside specified ranges must be documented and peptide integrity assessed.
⚠️ Common Storage Mistakes
Key Research Studies
• Retatrutide Phase 2 trials: Jastreboff AM, et al. (2023). "Triple-Hormone-Receptor Agonist for Obesity." N Engl J Med.
• SURMOUNT trials (Tirzepatide): Garvey WT, et al. (2023). "Tirzepatide for the treatment of obesity." JAMA.
• STEP trials (Semaglutide): Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med.
• Tesamorelin visceral fat reduction: Falutz J, et al. (2010). "Effects of tesamorelin on visceral fat in HIV-infected patients." N Engl J Med.
• BPC-157 tissue repair mechanisms: Sikiric P, et al. (2018). "Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract." Curr Pharm Des.
• TB-500 cardioprotection: Bock-Marquette I, et al. (2004). "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration." Nature.
• Growth hormone pathways: Veldhuis JD, et al. (2009). "Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition." Endocr Rev.
Institutional Resources
For complete research protocols, institutional guidelines, and updated safety information, consult your facility's research compliance office and current literature databases.
Medical & Research Disclaimer
This guide is intended exclusively for educational and research purposes by certified, authorized personnel. All information is provided for reference only and does not constitute medical advice, diagnosis, or treatment recommendations.
Peptide research must be conducted in compliance with all applicable institutional, local, and federal regulations. Individual results may vary. Always consult qualified healthcare professionals and institutional review boards before beginning any research protocol.
© 2026 Livnexa Research Institute. All rights reserved.